JPRN-UMIN000042163Completed未知

etwork meta-analysis for chemo-naive incurable not highly PD-L1-expressed squamous non-small cell lung cancer without confirmed driver alteration - Network meta-analysis for chemo-naive incurable not highly PD-L1-expressed squamous non-small cell lung cancer without confirmed driver alteration

Yokohama City University University Hospital0 sites22,619 target enrollmentStarted: October 20, 2020Last updated: October 17, 2023

Conditions

Trial Snapshot

Please see: Transl Lung Cancer Res. 2021 Aug;10(8):3550-3566. doi: 10.21037/tlcr-21-419.

•Kinase inhibitors targeting EGFR, ALK, ROS1, and BRAF are beyond our concern. A study focusing on patients with poor performance status or elderly should be excluded. A patient whose PD-L1 protein expression determined by tumor proportion score (TPS) is 50% or higher will be excluded because current guidelines recommends treatment option differently for those with TPS <50% and >=50%. If subset of study population fit our criteria, the data of the subset will be analyzed. For example, a study separately provide data of three populations whose TPS score is 0%, 1-49%, and 50-%, we will collect data of populations with TPS of 0% and 1-49%. Tumor mutation burden is not questioned. If a study focusses on patients with non-squamous NSCLC, driver alteration, or TPS of 50% or higher, the study should be excluded. However, a study without criteria regarding pathological subclassification of NSCLC, driver gene, and TPS is acceptable, otherwise most NSCLC studies will be excluded.

Sponsor